Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio is on track for the development nominee of their AATD program in the second quarter of 2026, with their current lead program, KRRO-121, being focused on treating hyperammonemia in urea cycle disorders and hepatic encephalopathy. The company has shown promising data for their subcutaneous RNA editing technology, with single-dose in vivo data showing high potency and repeat dosing achieving over 90% editing and protein correction. With a clear value proposition and a substantial market opportunity for their potential treatments, the company's stock has the potential for significant growth in the future.

Bears say

Korro Bio is a biopharmaceutical company with a unique approach to genetic medicines. Despite the promising science and potential for high peak sales, there are fundamental concerns about execution and regulatory expectations for their lead candidate KRRO-121 in hyperammonemia, with potential for limited efficacy and safety issues. The company's current valuation does not reflect these risks, leading to a negative outlook on the stock.

KRRO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 9 analysts, KRRO has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.